thalidomide and Deep Vein Thrombosis studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)."	9.16	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012)
"Patients receiving lenalidomide are at an increased risk for deep venous thrombosis (DVT)."	9.15	Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. ( Aue, G; Cullinane, AM; McCoy, P; Nelson Lozier, J; Samsel, L; Soto, S; Tian, X; Wiestner, A, 2011)
"We report the results of a non-randomized phase II study of low-dose thalidomide plus low-dose dexamethasone therapy in 66 patients with refractory multiple myeloma."	9.12	Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. ( Abe, M; Fujii, H; Fukuhara, T; Handa, H; Hata, H; Iida, S; Ishida, T; Ishii, A; Ishikawa, T; Kosaka, M; Miyata, A; Murakami, H; Oota, M; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Shimizu, K; Takagi, T; Takatsuki, K; Wakayama, T, 2007)
"Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen."	9.12	Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006)
"This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination."	9.12	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007)
"Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20."	9.12	Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006)
"We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis."	9.11	Treatment of cutaneous sarcoidosis with thalidomide. ( Cordoliani, F; Dupuy, A; Lebbé, C; Morel, P; Nguyen, YT; Rybojad, M; Vignon-Pennamen, MD, 2004)
"Daily low-dose aspirin (81 mg orally) given to patients with newly diagnosed and relapsed/refractory multiple myeloma who were receiving DVd-T reduced the incidence of VTEs without an increase in bleeding complications."	9.11	The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005)
"Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities."	9.11	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004)
"The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction chemotherapy with or without thalidomide, are reported in this study."	9.09	Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fink, L; Gopal, AV; Morris, C; Siegel, E; Toor, A; Tricot, G; Zangari, M, 2001)
"We presented a patient suffered from stroke related to thalidomide therapy."	8.84	[Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007)
"Thalidomide (Thal) treatment of patients with multiple myeloma (MM) is associated with vascular thrombosis, but the underlying mechanism is unknown."	7.81	Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro. ( Gao, Y; Liu, S; Ma, G; Su, Y; Teng, Y; Wang, Y, 2015)
"Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition."	7.80	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014)
"The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism."	7.75	Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009)
"Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen."	7.74	Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008)
"A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy."	7.74	Thromboembolic events with lenalidomide-based therapy for multiple myeloma. ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008)
"Thalidomide is the drug of choice in the treatment of severe erythema nodosum leprosum (ENL) in men."	7.74	A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008)
"Deep venous thrombosis (DVT) is a common complication of thalidomide treatment."	7.73	Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006)
"Venous thromboembolism (VTE) is a major complication in patients with multiple myeloma (MM) during treatment with thalidomide combined with chemotherapy and/or dexamethasone."	7.72	Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. ( De Groot, PG; Fijnheer, R; Lokhorst, HM; Minnema, MC, 2003)
"Thalidomide has antiangiogenic properties and was found to be effective in patients with multiple myeloma (MM) when used in the setting of posttransplantation relapse."	7.72	Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. ( Barlogie, B; Eddleman, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Talamo, G; Thertulien, R; Tricot, G; Van Rhee, F; Zangari, M, 2003)
"Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8."	7.72	Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. ( Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F, 2004)
"We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA."	7.71	Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002)
"Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%."	6.72	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006)
"The incidence of deep vein thrombosis (DVT) was significantly higher in the thalidomide arm hazard ratio: 4."	6.71	Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. ( Anaissie, E; Barlogie, B; Eddlemon, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Saghafifar, F; Talamo, G; Thertulien, R; Thomas, T; Tricot, G; Van Rhee, F; Zangari, M, 2004)
"Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i."	6.71	Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003)
"Thalidomide is an oral agent with significant activity in one-third of patients with refractory myeloma."	6.71	Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Poziopoulos, C; Xilouri, I; Zomas, A; Zorzou, MP, 2004)
"Multiple myeloma is a plasma cell malignancy that remains incurable with current treatment approaches including high-dose therapy and autologous stem cell transplantation."	6.43	Thalidomide and dexamethasone: therapy for multiple myeloma. ( Kumar, S; Rajkumar, SV, 2005)
"Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum."	5.39	Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. ( Burgués-Calderón, M; de la Hera, I; Fuertes, L; Hebe Petiti-Martin, G; Rivera-Díaz, R; Vanaclocha, F; Villar-Buill, M, 2013)
"Thalidomide was recently reported to reduce the severity and frequency of epistaxes in patients with hereditary haemorrhagic telangiectasia (HHT)."	5.37	Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. ( Hermans, C; Lambert, C; Penaloza, A; Vekemans, MC, 2011)
"As thalidomide has become an accepted component in therapeutic strategies for multiple myeloma, careful attention must be paid to the prevention of thrombosis."	5.33	[Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. ( Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Miyazawa, Y; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Uchiumi, H, 2006)
"Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)."	5.16	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012)
"Patients receiving lenalidomide are at an increased risk for deep venous thrombosis (DVT)."	5.15	Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. ( Aue, G; Cullinane, AM; McCoy, P; Nelson Lozier, J; Samsel, L; Soto, S; Tian, X; Wiestner, A, 2011)
"Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20."	5.12	Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006)
"Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen."	5.12	Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006)
" We have analyzed the prognostic impact of the development of a thrombotic episode in newly diagnosed multiple myeloma patients who received chemotherapy either with or without thalidomide on our Total Therapy 2 protocol."	5.12	Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. ( Barlogie, B; Bolejack, V; Cavallo, F; Fink, L; Tricot, G; Zangari, M, 2007)
"We report the results of a non-randomized phase II study of low-dose thalidomide plus low-dose dexamethasone therapy in 66 patients with refractory multiple myeloma."	5.12	Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. ( Abe, M; Fujii, H; Fukuhara, T; Handa, H; Hata, H; Iida, S; Ishida, T; Ishii, A; Ishikawa, T; Kosaka, M; Miyata, A; Murakami, H; Oota, M; Ozaki, S; Sakai, A; Sawamura, M; Shimazaki, C; Shimizu, K; Takagi, T; Takatsuki, K; Wakayama, T, 2007)
"The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum."	5.12	Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007)
"This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination."	5.12	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007)
"Daily low-dose aspirin (81 mg orally) given to patients with newly diagnosed and relapsed/refractory multiple myeloma who were receiving DVd-T reduced the incidence of VTEs without an increase in bleeding complications."	5.11	The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005)
"We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis."	5.11	Treatment of cutaneous sarcoidosis with thalidomide. ( Cordoliani, F; Dupuy, A; Lebbé, C; Morel, P; Nguyen, YT; Rybojad, M; Vignon-Pennamen, MD, 2004)
"Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities."	5.11	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004)
" We report the results of a prospective randomized trial of 62 newly diagnosed MM patients tested at baseline for hypercoagulability and treated with intensive chemotherapy with or without thalidomide in a randomized fashion."	5.10	Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M, 2002)
" Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT."	5.10	Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. ( Anaissie, E; Barlogie, B; Fassas, A; Fink, L; Morris, C; Saghafifar, F; Siegel, E; Tricot, G; Zangari, M, 2002)
"We conclude that the combination of thalidomide plus dexamethasone is a feasible and active regimen in the treatment of multiple myeloma."	5.10	Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, S; Iturria, N; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2002)
"The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction chemotherapy with or without thalidomide, are reported in this study."	5.09	Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fink, L; Gopal, AV; Morris, C; Siegel, E; Toor, A; Tricot, G; Zangari, M, 2001)
"After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma."	4.86	Palliative oncology: thalidomide. ( Prommer, EE, 2010)
" We report a case of deep venous thrombosis (DVT) and pulmonary embolus (PE) following thalidomide use in a patient with leprosy (erythema nodosum leprosum, ENL) who was concurrently treated with prednisone, as well as a review of relevant literature."	4.85	Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. ( Boone, SL; Fabi, SG; Hill, C; West, DP; Witherspoon, JN, 2009)
"With the increase in the number of reports and trials on the use of thalidomide as a part of the treatment of different medical conditions, particularly multiple myeloma (MM), it was observed that this drug might be associated with an increase in the risk of venous thromboembolic (VTE) events."	4.84	Thalidomide and thrombosis. A meta-analysis. ( El Accaoui, RN; Shamseddeen, WA; Taher, AT, 2007)
"Lenalidomide, an analog of thalidomide, is an effective new treatment for multiple myeloma."	4.84	Risk of thrombosis with lenalidomide and its prevention with aspirin. ( Hirsh, J, 2007)
"We presented a patient suffered from stroke related to thalidomide therapy."	4.84	[Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007)
"Thalidomide (Thal) treatment of patients with multiple myeloma (MM) is associated with vascular thrombosis, but the underlying mechanism is unknown."	3.81	Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro. ( Gao, Y; Liu, S; Ma, G; Su, Y; Teng, Y; Wang, Y, 2015)
"Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition."	3.80	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014)
"Combining thalidomide (Thal) with chemotherapeutic agents or steroid preparations led to improved response rates in the treatment of multiple myeloma."	3.77	Activation of coagulation by a thalidomide-based regimen. ( Chung, J; Hoshi, A; Isozumi, Y; Koyama, T; Matsumoto, A, 2011)
"The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism."	3.75	Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009)
"Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen."	3.74	Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008)
"A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy."	3.74	Thromboembolic events with lenalidomide-based therapy for multiple myeloma. ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008)
"Thalidomide is the drug of choice in the treatment of severe erythema nodosum leprosum (ENL) in men."	3.74	A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008)
"A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide."	3.74	Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. ( Baris, D; Bell, SE; Child, JA; Cocks, K; Corthals, S; Crowley, J; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Haessler, J; Hoering, A; Jackson, G; Johnson, DC; Morgan, GJ; Rajkumar, SV; Ramos, C; Sonneveld, P; Van Ness, B, 2008)
"Deep venous thrombosis (DVT) is a common complication of thalidomide treatment."	3.73	Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006)
"Venous thromboembolism (VTE) is a major complication in patients with multiple myeloma (MM) during treatment with thalidomide combined with chemotherapy and/or dexamethasone."	3.72	Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. ( De Groot, PG; Fijnheer, R; Lokhorst, HM; Minnema, MC, 2003)
"Thalidomide has antiangiogenic properties and was found to be effective in patients with multiple myeloma (MM) when used in the setting of posttransplantation relapse."	3.72	Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. ( Barlogie, B; Eddleman, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Talamo, G; Thertulien, R; Tricot, G; Van Rhee, F; Zangari, M, 2003)
"Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8."	3.72	Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. ( Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F, 2004)
"In this report, we describe two new venous thrombosis cases occurring during a treatment with thalidomide."	3.71	[Thrombotic accidents induced by thalidomide: two cases]. ( Gachon, J; Grob, JJ; Richard, MA, 2002)
"We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA."	3.71	Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002)
"Lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment."	2.73	A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. ( Cooper, A; Forbes, A; Hawkey, CJ; Hawthorne, AB; Manning, DC; Mansfield, JC; Parkes, M; Perowne, RC; Probert, CS; Zeldis, JB, 2007)
"Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%."	2.72	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006)
"Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy."	2.72	Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. ( Chanan-Khan, A; Depaolo, D; Dimicelli, L; Doran, V; Landrigan, B; Marshal, P; Miller, KC; Padmanabhan, S; Yu, J, 2006)
"The incidence of deep vein thrombosis (DVT) was significantly higher in the thalidomide arm hazard ratio: 4."	2.71	Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. ( Anaissie, E; Barlogie, B; Eddlemon, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Saghafifar, F; Talamo, G; Thertulien, R; Thomas, T; Tricot, G; Van Rhee, F; Zangari, M, 2004)
"Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i."	2.71	Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003)
"Thalidomide is an oral agent with significant activity in one-third of patients with refractory myeloma."	2.71	Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. ( Anagnostopoulos, A; Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Poziopoulos, C; Xilouri, I; Zomas, A; Zorzou, MP, 2004)
"Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen combining melphalan and prednisone (MP)."	2.45	How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. ( Gay, F; Palumbo, A, 2009)
"Multiple myeloma is a plasma cell malignancy that remains incurable with current treatment approaches including high-dose therapy and autologous stem cell transplantation."	2.43	Thalidomide and dexamethasone: therapy for multiple myeloma. ( Kumar, S; Rajkumar, SV, 2005)
"Cerebral venous thrombosis is a relatively uncommon condition afflicting mostly young adults."	2.43	Unusual causes of cerebral venous thrombosis. ( AlKawi, A; Ilyas, A; Ilyas, MS; Khatri, IA, 2006)
"Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)."	1.39	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013)
"Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum."	1.39	Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. ( Burgués-Calderón, M; de la Hera, I; Fuertes, L; Hebe Petiti-Martin, G; Rivera-Díaz, R; Vanaclocha, F; Villar-Buill, M, 2013)
"Thalidomide was recently reported to reduce the severity and frequency of epistaxes in patients with hereditary haemorrhagic telangiectasia (HHT)."	1.37	Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. ( Hermans, C; Lambert, C; Penaloza, A; Vekemans, MC, 2011)
"As thalidomide has become an accepted component in therapeutic strategies for multiple myeloma, careful attention must be paid to the prevention of thrombosis."	1.33	[Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. ( Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Miyazawa, Y; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Uchiumi, H, 2006)

Research

Studies (81)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	66 (81.48)	29.6817
2010's	14 (17.28)	24.3611
2020's	1 (1.23)	2.80

Authors	Studies
Cornell, RF	1
Goldhaber, SZ	1
Engelhardt, BG	1
Moslehi, J	1
Jagasia, M	1
Harrell, S	1
Rubinstein, SM	1
Hall, R	1
Wyatt, H	1
Piazza, G	1
Chhabria, BA	1
Pannu, AK	1
Bhalla, A	1
Bagratuni, T	1
Kastritis, E	2
Politou, M	1
Roussou, M	1
Kostouros, E	1
Gavriatopoulou, M	1
Eleutherakis-Papaiakovou, E	1
Kanelias, N	1
Terpos, E	3
Dimopoulos, MA	4
Katodritou, E	2
Vadikolia, C	1
Lalagianni, C	1
Kotsopoulou, M	1
Papageorgiou, G	1
Kyrtsonis, MC	2
Matsouka, P	1
Giannakoulas, N	1
Kyriakou, D	1
Karras, G	1
Anagnostopoulos, N	3
Michali, E	1
Briasoulis, E	1
Hatzimichael, E	1
Spanoudakis, E	1
Zikos, P	1
Tsakiridou, A	1
Tsionos, K	1
Anargyrou, K	1
Symeonidis, A	1
Maniatis, A	2
Gao, Y	1
Ma, G	1
Liu, S	1
Teng, Y	1
Wang, Y	1
Su, Y	1
Vetrichevvel, TP	1
Pise, GA	1
Thappa, DM	1
Johnson, DC	1
Corthals, S	1
Ramos, C	1
Hoering, A	1
Cocks, K	1
Dickens, NJ	1
Haessler, J	1
Goldschmidt, H	2
Child, JA	1
Bell, SE	1
Jackson, G	1
Baris, D	1
Rajkumar, SV	8
Davies, FE	1
Durie, BG	1
Crowley, J	1
Sonneveld, P	4
Van Ness, B	1
Morgan, GJ	1
Talamo, GP	1
Ibrahim, S	1
Claxton, D	1
Tricot, GJ	1
Fink, LM	1
Zangari, M	8
Tewari, P	1
Kenny, E	1
Staines, A	1
Chanock, S	1
Browne, P	1
Lawler, M	1
Fabi, SG	1
Hill, C	1
Witherspoon, JN	1
Boone, SL	1
West, DP	1
Prommer, EE	1
Palumbo, A	4
Gay, F	1
Auwerda, JJ	3
Yuana, Y	1
Osanto, S	1
de Maat, MP	1
Bertina, RM	1
Leebeek, FW	2
Offidani, M	3
Corvatta, L	3
Polloni, C	1
Gentili, S	1
Brioni, A	1
Visani, G	1
Galieni, P	1
Brunori, M	2
Alesiani, F	1
Catarini, M	3
Centurioni, R	1
Samori, A	1
Blasi, N	1
Ferranti, M	1
Fraticelli, P	1
Mele, A	2
Rizzi, R	1
Larocca, F	1
Leoni, P	3
Hoshi, A	1
Matsumoto, A	1
Chung, J	1
Isozumi, Y	1
Koyama, T	1
Aue, G	1
Nelson Lozier, J	1
Tian, X	1
Cullinane, AM	1
Soto, S	1
Samsel, L	1
McCoy, P	1
Wiestner, A	1
Larocca, A	1
Cavallo, F	2
Bringhen, S	2
Di Raimondo, F	1
Falanga, A	1
Evangelista, A	1
Cavalli, M	1
Stanevsky, A	1
Corradini, P	1
Pezzatti, S	1
Patriarca, F	1
Cavo, M	2
Peccatori, J	1
Catalano, L	1
Carella, AM	1
Cafro, AM	1
Siniscalchi, A	1
Crippa, C	2
Petrucci, MT	1
Yehuda, DB	1
Beggiato, E	1
Di Toritto, TC	1
Boccadoro, M	2
Nagler, A	1
Penaloza, A	1
Vekemans, MC	1
Lambert, C	1
Hermans, C	1
Eudo, C	1
Petit, A	1
Mondon, K	1
Rippault, H	1
Dardaine, V	1
Constans, T	1
Hommet, C	1
Cottier, JP	1
Yamaguchi, S	1
Yamamoto, Y	1
Hosokawa, A	1
Hagiwara, K	1
Uezato, H	1
Takahashi, K	1
Hebe Petiti-Martin, G	1
Villar-Buill, M	1
de la Hera, I	1
Fuertes, L	1
Burgués-Calderón, M	1
Rivera-Díaz, R	1
Vanaclocha, F	1
Siegel, E	3
Barlogie, B	6
Anaissie, E	4
Saghafifar, F	3
Fassas, A	4
Morris, C	3
Fink, L	6
Tricot, G	6
Zamagni, E	1
Cellini, C	1
Tosi, P	1
Cangini, D	1
Cini, M	1
Valdrè, L	1
Palareti, G	1
Masini, L	1
Tura, S	1
Baccarani, M	1
Gachon, J	1
Grob, JJ	1
Richard, MA	1
Hayman, S	1
Gertz, MA	1
Dispenzieri, A	1
Lacy, MQ	1
Greipp, PR	1
Geyer, S	1
Iturria, N	1
Fonseca, R	1
Lust, JA	1
Kyle, RA	1
Witzig, TE	1
Bennett, CL	1
Schumock, GT	1
Desai, AA	1
Kwaan, HC	1
Raisch, DW	1
Newlin, R	1
Stadler, W	1
Horne, MK	1
Figg, WD	1
Arlen, P	1
Gulley, J	1
Parker, C	1
Lakhani, N	1
Parnes, H	1
Dahut, WL	1
Steurer, M	1
Sudmeier, I	1
Stauder, R	1
Gastl, G	1
Santos, AB	1
Llamas, P	1
Román, A	1
Prieto, E	1
De Oña, R	1
De Velasco, JF	1
Tomás, JF	1
Thertulien, R	2
Jacobson, J	2
Eddleman, P	1
Van Rhee, F	2
Talamo, G	2
Lee, CK	2
Minnema, MC	3
Fijnheer, R	1
De Groot, PG	2
Lokhorst, HM	3
Kropff, MH	1
Lang, N	1
Bisping, G	1
Dominé, N	1
Innig, G	1
Hentrich, M	1
Mitterer, M	1
Südhoff, T	1
Fenk, R	1
Straka, C	1
Heinecke, A	1
Koch, OM	1
Ostermann, H	1
Berdel, WE	1
Kienast, J	1
Marconi, M	2
Olivieri, A	2
Nguyen, YT	1
Dupuy, A	1
Cordoliani, F	1
Vignon-Pennamen, MD	1
Lebbé, C	1
Morel, P	1
Rybojad, M	1
Hamilos, G	1
Zomas, A	2
Gika, D	1
Efstathiou, E	1
Grigoraki, V	1
Poziopoulos, C	1
Xilouri, I	1
Zorzou, MP	1
Anagnostopoulos, A	2
Malerba, L	1
Candela, M	1
Capelli, D	1
Montanari, M	1
Rupoli, S	1
Eddlemon, P	1
Thomas, T	1
Galli, M	1
Elice, F	1
Comotti, B	1
Rodeghiero, F	1
Barbui, T	1
Eleutherakis-Papaiakovou, V	1
Breitkreutz, I	1
van der Holt, B	1
Cremer, FW	1
van Marion, AM	2
Westveer, PH	1
Silingardi, M	1
Iotti, M	1
Trenti, C	1
Salvarani, C	1
Iori, I	1
Rus, C	1
Bazzan, M	1
Sharma, NL	2
Sharma, V	1
Shanker, V	2
Mahajan, VK	2
Sarin, S	1
Streetly, M	1
Hunt, BJ	1
Parmar, K	1
Jones, R	1
Zeldis, J	3
Schey, S	1
Kumar, S	1
Rajkumar, VS	1
Baz, R	1
Li, L	1
Kottke-Marchant, K	1
Srkalovic, G	1
McGowan, B	1
Yiannaki, E	1
Karam, MA	1
Faiman, B	1
Jawde, RA	1
Andresen, S	1
Hussein, MA	1
van Oosterom, R	1
Adelmeijer, J	1
Lisman, T	1
Repoussis, P	1
Delibasi, S	1
Vassou, A	1
Pouli, A	1
Zervas, K	1
Burton, A	1
Ikhlaque, N	1
Seshadri, V	1
Kathula, S	1
Baumann, MA	2
Knight, R	2
DeLap, RJ	1
Zeldis, JB	2
Blood, E	2
Mita, MM	1
Rowinsky, EK	1
Forero, L	1
Eckhart, SG	1
Izbicka, E	1
Weiss, GR	1
Beeram, M	1
Mita, AC	1
de Bono, JS	1
Tolcher, AW	1
Hammond, LA	1
Simmons, P	1
Berg, K	1
Takimoto, C	1
Patnaik, A	1
Richardson, PG	1
Mitsiades, CS	1
Jagannath, S	1
Zeldenrust, SR	1
Alsina, M	1
Schlossman, RL	1
Desikan, KR	1
Hideshima, T	1
Munshi, NC	1
Kelly-Colson, K	1
Doss, D	1
McKenney, ML	1
Gorelik, S	1
Warren, D	1
Freeman, A	1
Rich, R	1
Wu, A	1
Olesnyckyj, M	1
Wride, K	1
Dalton, WS	1
Weller, E	1
Anderson, KC	1
Miyazawa, Y	1
Irisawa, H	1
Uchiumi, H	1
Saitoh, T	1
Handa, H	2
Matsushima, T	1
Tsukamoto, N	1
Karasawa, M	1
Murakami, H	2
Nojima, Y	1
Krown, SE	1
Niedzwiecki, D	1
Hwu, WJ	1
Hodgson, L	1
Houghton, AN	1
Haluska, FG	1
Miller, KC	1
Padmanabhan, S	1
Dimicelli, L	1
Depaolo, D	1
Landrigan, B	1
Yu, J	1
Doran, V	1
Marshal, P	1
Chanan-Khan, A	1
Khatri, IA	1
AlKawi, A	1
Ilyas, A	1
Ilyas, MS	1
Hirsh, J	1
Dunkley, S	1
Gaudry, L	1
Chennuru, S	1
El Accaoui, RN	1
Shamseddeen, WA	1
Taher, AT	1
Mansfield, JC	1
Parkes, M	1
Hawthorne, AB	1
Forbes, A	1
Probert, CS	1
Perowne, RC	1
Cooper, A	1
Manning, DC	1
Hawkey, CJ	1
Abe, M	1
Iida, S	1
Ishii, A	1
Ishikawa, T	1
Ishida, T	1
Oota, M	1
Ozaki, S	1
Kosaka, M	1
Sakai, A	1
Sawamura, M	1
Shimazaki, C	1
Shimizu, K	1
Takagi, T	1
Hata, H	1
Fukuhara, T	1
Fujii, H	1
Miyata, A	1
Wakayama, T	1
Takatsuki, K	1
Sharma, VC	1
Ranjan, N	1
Gupta, M	1
Bolejack, V	1
Ito, Y	1
Mori, A	1
Yonemura, K	1
Hashimoto, Y	1
Hirano, T	1
Uchino, M	1
Dimopoulos, M	1
Alkindi, S	1
Dennison, D	1
Pathare, A	1
Menon, SP	1
Lacy, M	1
Falco, P	1
Jeng, WJ	1
Kuo, MC	1
Shih, LY	1
Chu, PH	1
Esteve, E	1
Legac, E	1
Osman, K	1
Comenzo, R	1
Badros, A	2
Desikan, R	2
Gopal, AV	1
Toor, A	2
Strupp, C	1
Germing, U	1
Aivado, M	1
Misgeld, E	1
Haas, R	1
Gattermann, N	1
Mehta, P	1
Whitfield, D	1
Escudier, B	1
Lassau, N	1
Leborgne, S	1
Angevin, E	1
Laplanche, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma[NCT00028886]	Phase 3	450 participants (Anticipated)	Interventional	2001-03-31	Active, not recruiting
A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma[NCT00033332]	Phase 3	0 participants	Interventional	2002-04-30	Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]	Phase 3	105 participants (Anticipated)	Interventional	2014-04-30	Recruiting
A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT00439231]	Phase 2	33 participants (Actual)	Interventional	2007-02-28	Completed
Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978]		140 participants (Actual)	Observational	2022-09-01	Completed
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928]	Phase 3	402 participants (Actual)	Interventional	2007-06-30	Active, not recruiting
An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484]	Phase 2	56 participants (Actual)	Interventional	2005-12-31	Completed
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235]	Phase 3	260 participants (Anticipated)	Interventional	2005-03-31	Completed
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747]	Phase 3	390 participants (Anticipated)	Interventional	2006-03-31	Completed
A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.[NCT00388635]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2004-04-30	Completed
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839]	Phase 2	21 participants (Actual)	Interventional	2012-02-22	Completed
An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma[NCT00044018]	Phase 2	102 participants (Actual)	Interventional	2002-04-01	Completed
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332]	Phase 2	12 participants (Actual)	Interventional	2016-12-12	Terminated (stopped due to FDA Hold Due to Updated Risks)
QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363]	Phase 3	120 participants (Actual)	Interventional	2007-05-31	Completed
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma[NCT05199311]	Phase 1/Phase 2	66 participants (Anticipated)	Interventional	2022-05-13	Recruiting
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725]	Phase 1	14 participants (Actual)	Interventional	2019-08-29	Active, not recruiting
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109]	Phase 2	188 participants (Anticipated)	Interventional	2020-10-21	Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease[NCT00446433]	Phase 2	90 participants	Interventional	2002-03-31	Completed
Safety and Efficacy Assessments of Osalmid in the Treatment of Multiple Myeloma[NCT03670173]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2018-10-01	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To establish the overall response rate based on peripheral blood measures (absolute neutrophil count, platelets, and/or hemoglobin), lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; and bone marrow biopsy measured at 24 weeks after first dose of lenalidomide using this dosing regimen (NCT00439231)
Timeframe: 24 weeks of lenalidomide therapy

Complete Response

Intervention	participants (Number)
	Complete response	Partial response	No response
CLL Subject Response Rate After Lenalidomide Therapy	0	5	28

Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles

Overall Response Rate

Intervention	Percentage of Participants (Number)
FCR With Lenalidomide	45

Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles

Evaluation of Stringent Complete Response, Complete Response, and Very Good Partial Response Rate (sCR + CR + VGPR Rate).

Intervention	Percentage of Participants (Number)
FCR With Lenalidomide	95

Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.

Number of Participants Serious Adverse Events

Intervention	Participants (Count of Participants)
Pembrolizumab + Lenalidomide	11

Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years

Number of Participants Who Progressed at 12 Months

Intervention	Participants (Count of Participants)
Pembrolizumab + Lenalidomide	1

Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.

Progression Free Survival (PFS)

Intervention	Participants (Count of Participants)
Pembrolizumab + Lenalidomide	10

PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years

Article	Year
Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:8 Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous	2009
Palliative oncology: thalidomide. The American journal of hospice & palliative care, 2010, Volume: 27, Issue:3 Topics: Angiogenesis Inhibitors; Constipation; Cytokines; Drug Eruptions; Humans; Hydrolysis; Hypotension, O	2010
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology. American Society of Hematology. Education Program, 2009 Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot	2009
Thalidomide-associated deep vein thrombosis and pulmonary embolism. The American journal of medicine, 2002, Volume: 113, Issue:7 Topics: Angiogenesis Inhibitors; Humans; Pulmonary Embolism; Thalidomide; Venous Thrombosis	2002
Adverse effects of thalidomide administration in patients with neoplastic diseases. The American journal of medicine, 2004, Oct-01, Volume: 117, Issue:7 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials, Phase II	2004
Thalidomide and dexamethasone: therapy for multiple myeloma. Expert review of anticancer therapy, 2005, Volume: 5, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dexamethasone; Humans; Multiple Myeloma;	2005
Unusual causes of cerebral venous thrombosis. JPMA. The Journal of the Pakistan Medical Association, 2006, Volume: 56, Issue:11 Topics: Cerebral Veins; Crohn Disease; Humans; Infections; Intracranial Thrombosis; Risk Factors; Sinus Thro	2006
Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest, 2007, Volume: 131, Issue:1 Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Humans; Lenalidomide; Multiple Myeloma; Thalidomide;	2007
Thalidomide and thrombosis. A meta-analysis. Thrombosis and haemostasis, 2007, Volume: 97, Issue:6 Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Mul	2007
[Brief report: stroke in multiple myeloma patient treated with thalidomide]. Rinsho shinkeigaku = Clinical neurology, 2007, Volume: 47, Issue:9 Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple	2007

Article	Year
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. British journal of haematology, 2020, Volume: 190, Issue:4 Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm	2020
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thrombosis and haemostasis, 2011, Volume: 105, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control	2011
Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. American journal of hematology, 2011, Volume: 86, Issue:10 Topics: Adult; Aged; Blood Coagulation; Endothelium, Vascular; Female; Humans; Inflammation; Lenalidomide; L	2011
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, Jan-26, Volume: 119, Issue:4 Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri	2012
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 2002, Aug-15, Volume: 100, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E	2002
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. British journal of haematology, 2003, Volume: 121, Issue:1 Topics: Aged; Anticoagulants; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Heparin, Low-Mole	2003
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British journal of haematology, 2003, Volume: 122, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem	2003
Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica, 2003, Volume: 88, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; M	2003
Treatment of cutaneous sarcoidosis with thalidomide. Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:2 Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Male; Middle Aged	2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents	2004
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. European journal of haematology, 2004, Volume: 72, Issue:6 Topics: Aged; Aged, 80 and over; Constipation; Disorders of Excessive Somnolence; Dose-Response Relationship	2004
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British journal of haematology, 2004, Volume: 126, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans;	2004
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia, 2004, Volume: 18, Issue:12 Topics: Adolescent; Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso	2004
Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fibrinolytic Agents; Humans; Multiple Myeloma;	2004
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic proceedings, 2005, Volume: 80, Issue:12 Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Dexamethasone; Doxorubicin; D	2005
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thrombosis and haemostasis, 2005, Volume: 94, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bloo	2005
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica, 2006, Volume: 91, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free	2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug;	2007
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido	2006
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer, 2006, Oct-15, Volume: 107, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2006
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukemia & lymphoma, 2006, Volume: 47, Issue:11 Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male	2006
A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Alimentary pharmacology & therapeutics, 2007, Aug-01, Volume: 26, Issue:3 Topics: Adolescent; Adult; Aged; Crohn Disease; Double-Blind Method; Female; Humans; Immunosuppressive Agent	2007
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European journal of haematology, 2007, Volume: 79, Issue:3 Topics: Adult; Aged; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Male; Midd	2007
Thalidomide: an experience in therapeutic outcome and adverse reactions. The Journal of dermatological treatment, 2007, Volume: 18, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen	2007
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:7 Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combi	2007
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 2001, Sep-01, Volume: 98, Issue:5 Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Facto	2001
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3 Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood C	2002

Article	Year
Venous thrombo-embolism: thalidomide and leprosy. QJM : monthly journal of the Association of Physicians, 2017, Jun-01, Volume: 110, Issue:6 Topics: Computed Tomography Angiography; Electrocardiography; Erythema Nodosum; Humans; Leprosy, Lepromatous	2017
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. American journal of hematology, 2013, Volume: 88, Issue:9 Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Diseas	2013
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dex	2014
Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro. Thrombosis research, 2015, Volume: 135, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Antigens, CD; Coagulants; Dexamethasone; Endothelial Cells; Endothel	2015
A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. Leprosy review, 2008, Volume: 79, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide; V	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Case-Control Studies; Clinical Trials as Topic; Cytokines; Data Collection; DNA Repair; Gene Express	2008
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5 Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che	2009
Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide. Blood, 2009, May-28, Volume: 113, Issue:22 Topics: Angiogenesis Inhibitors; Case-Control Studies; DNA Helicases; Genetic Predisposition to Disease; Hum	2009
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leukemia & lymphoma, 2011, Volume: 52, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Inci	2011
Activation of coagulation by a thalidomide-based regimen. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:6 Topics: Annexin A5; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Blood Coagulation Factors; Cel	2011
Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:7 Topics: Activin Receptors, Type II; Contraindications; Epistaxis; Female; Humans; Middle Aged; Mutation; Tel	2011
Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide. Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:12 Topics: Aged, 80 and over; Antineoplastic Agents; Female; Humans; Intracranial Thrombosis; Lenalidomide; Mul	2011
Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy. The Journal of dermatology, 2012, Volume: 39, Issue:8 Topics: Adrenal Cortex Hormones; Cyclosporine; Humans; Leprostatic Agents; Leprosy; Male; Middle Aged; Pulmo	2012
Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. Actas dermo-sifiliograficas, 2013, Volume: 104, Issue:1 Topics: Adult; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Thalidomide; Venous Thrombosis	2013
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood, 2002, Sep-15, Volume: 100, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Incidence; Multiple Myeloma;	2002
[Thrombotic accidents induced by thalidomide: two cases]. La Revue de medecine interne, 2002, Volume: 23, Issue:8 Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Vulgaris; Male; Melanoma; Multiple Myel	2002
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy, 2003, Volume: 23, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Paclitax	2003
Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. British journal of haematology, 2003, Volume: 122, Issue:1 Topics: Angiogenesis Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Venous Thrombosis	2003
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clinical lymphoma, 2003, Volume: 4, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosp	2003
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Factor VIII; Female;	2003
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica, 2004, Volume: 89, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Drug Synergism; Erythropoieti	2004
Thalidomide, deep venous thrombosis and vasculitis. Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:11 Topics: Aged; Female; Humans; Lupus Erythematosus, Systemic; Thalidomide; Vasculitis; Venous Thrombosis	2004
Deep vein thrombosis: a rare complication of thalidomide therapy in recurrent erythema nodosum leprosum. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 2004, Volume: 72, Issue:4 Topics: Adult; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Erythema Nodosum; Female; Glucoco	2004
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. European journal of haematology, 2005, Volume: 74, Issue:4 Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; Hum	2005
Treatment options and considerations for the newly diagnosed myeloma patient. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Enoxapar	2005
Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic proceedings, 2005, Volume: 80, Issue:12 Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunosuppressive Agents; Multiple	2005
Thalidomide gives food for thought in multiple myeloma. The Lancet. Oncology, 2006, Volume: 7, Issue:4 Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; H	2006
Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. American journal of hematology, 2006, Volume: 81, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Cohort Studies; Female; Hem	2006
Lenalidomide and venous thrombosis in multiple myeloma. The New England journal of medicine, 2006, May-11, Volume: 354, Issue:19 Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Humans; Lenalido	2006
Lenalidomide and venous thrombosis in multiple myeloma. The New England journal of medicine, 2006, May-11, Volume: 354, Issue:19 Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple M	2006
[Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:7 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Administration Schedul	2006
Anticoagulation regimens for thalidomide and lenalidomide. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:9 Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Heparin, Low-Molecular-Weight; Human	2006
Thalidomide causes platelet activation, which can be abrogated by aspirin. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:6 Topics: Aspirin; Blood Platelets; Cell Aggregation; Humans; Monocytes; P-Selectin; Platelet Activation; Plat	2007
Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin. Internal medicine journal, 2007, Volume: 37, Issue:7 Topics: Aged; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myel	2007
How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Leukemia & lymphoma, 2007, Volume: 48, Issue:12 Topics: Antineoplastic Agents; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalid	2007
Arterial and venous thrombotic complications with thalidomide in multiple myeloma. Archives of medical research, 2008, Volume: 39, Issue:2 Topics: Administration, Oral; Aged; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple My	2008
Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer, 2008, Apr-01, Volume: 112, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinati	2008
Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. International journal of hematology, 2008, Volume: 87, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma;	2008
[Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide]. Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:2 Topics: Adult; Anticoagulants; Humans; Immunosuppressive Agents; International Normalized Ratio; Male; Pulmo	2001
Deep venous thrombosis and thalidomide therapy for multiple myeloma. The New England journal of medicine, 2001, Jun-21, Volume: 344, Issue:25 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; Thalidomide; Venous Thromb	2001
Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia, 2002, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transf	2002
Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders. Haematologica, 2002, Volume: 87, Issue:4 Topics: Hematologic Diseases; Humans; Salvage Therapy; Thalidomide; Treatment Outcome; Venous Thrombosis	2002
Thalidomide and venous thrombosis. Annals of internal medicine, 2002, May-07, Volume: 136, Issue:9 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Liver Neoplasms; Thalidomide; Venous Thrombo	2002

thalidomide and Deep Vein Thrombosis